CORT— CORCEPT THERAPEUTICS INC

MaterialsPharmaceuticals$12.2B mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Product revenue, net	$761.4M+12.8%	$675.0M+39.9%	$482.4M+20.0%	$401.9M
Cost of sales	$13.0M+19.3%	$10.9M+67.9%	$6.5M+20.4%	$5.4M
Research and development	$254.9M+3.2%	$246.9M+33.9%	$184.4M+40.7%	$131.0M
Selling, general and administrative	$448.7M+60.1%	$280.3M+52.1%	$184.3M+20.6%	$152.8M
Total operating expenses	$716.6M+33.2%	$538.1M+43.5%	$375.1M+29.7%	$289.2M
Income from operations	$44.8M-67.3%	$137.0M+27.7%	$107.3M-4.8%	$112.6M
Interest and other income	$21.7M-11.7%	$24.5M+42.1%	$17.3M+385.7%	$3.6M
Income before income taxes	$66.5M-58.8%	$161.5M+29.7%	$124.6M+7.2%	$116.2M
Income tax benefit (expense)	$33.2M+263.6%	-$20.3M-10.1%	-$18.4M-24.7%	-$14.8M
Net income	$99.7M-29.4%	$141.2M+33.0%	$106.1M+4.7%	$101.4M
Net income attributable to common stockholders, basic	$98.2M-29.7%	$139.7M+32.5%	$105.5M+4.2%	$101.3M
Net income attributable to common stockholders, diluted	$98.2M-29.7%	$139.7M+32.5%	$105.5M+4.2%	$101.3M
Basic net income per share (in dollars per share)	$950.00-29.6%	$1350.00+32.4%	$1020.00+7.4%	$950.00
Diluted net income per share (in dollars per share)	$820.00-33.3%	$1230.00+30.9%	$940.00+8.0%	$870.00
Basic (in shares)	103.9M+0.6%	103.2M-0.3%	103.6M-3.0%	106.8M
Diluted (in shares)	120.0M+5.7%	113.5M+1.6%	111.7M-3.6%	116.0M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 12 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.